公共可用的临床试验安全数据:审查和呼吁标准化和改进报告实践
Barbara A Hendrickson1, Cynthia McShea2, Tarek A Hammad3
1Department of Pediatrics, University of Chicago, Chicago, IL, USA. bhendric@bsd.uchicago.edu.
Pharmaceutical medicine
|December 16, 2025
概括
公开的临床试验安全数据缺乏一致性和细节性,影响药物开发和监管报告. 改善接触数据和EOI识别方法的获取对于药物监测至关重要.
科学领域:
- 药监和药物安全 药监和药物安全
- 临床试验数据透明度临床试验数据透明度
- 监管科学 监管科学
背景情况:
- 对利益相关者来说,对临床试验安全数据的可理解报告至关重要,包括监管安全报告.
- 公共来源中的安全事件感兴趣 (EOI) 信息的一致性和完整性尚未得到充分理解.
- 本研究评估了公开临床试验数据中的不良事件 (AE) 信息的可用性和透明度.
研究的目的:
- 检查公共临床试验数据源对信号检测的有用性.
- 评估严重或严重 (等级≥3) 利率事件 (EOI) 的上下文化.
- 评估不良事件信息的可用性和透明度.
主要方法:
- 对10种在美国和欧盟批准的药物进行了44种EOI的结构化审查.
- 来自期刊出版物,clinicaltrials.gov,FDA,EPAR和产品标签的评估安全数据.
- 评估参数包括人口统计,疾病严重程度,SAE频率,暴露调整率和EOI识别清晰度.
主要成果:
- 药物@FDA和EPAR的临床摘要提供了最多的参与者特征数据.
- 大多数出版物提供了人口统计和疾病严重程度数据;地理是不太常见的.
- 除产品标签外,SAE频率一般可用;EOI信息最常见于Drugs@FDA和EPAR.
- 临床试验.gov缺乏事件裁决细节和曝光调整率.
- 所有来源经常忽略了治疗暴露时间和明确的EOI识别方法;很少使用标准化查询.
结论:
- 公开的临床试验数据往往缺乏将严重/严重EOI率置于背景下所需的细节.
- 改善对治疗暴露数据的访问和更清晰的EOI识别是必不可少的.
- 提高安全信息的可用性支持药物监测,并改善利益风险评估.
相关概念视频
Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Hazard Ratio
543
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
543
Drug Regulation
2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
Bioavailability Study Design: Healthy Subjects Versus Patients
126
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
126


